Decreased pancreatic CCK receptor binding and CCK-stimulated amylase release in Zucker obese rats.
In Zucker obese rats the response to the effects of CCK on food intake and pancreatic exocrine function are decreased. However, it is unknown whether the decreased responsiveness is due to decreased receptor number and/or sensitivity or abnormal circulating concentrations of CCK. In these experiments percent total binding of 125I-CCK-33 to pancreatic acini from obese rats was one-half that in lean rats when data was expressed on a per microgram DNA basis (19.6 +/- 5.1 vs. 47.4 +/- 11.4, p less than 0.01). In a second experiment while the maximally effective dose of CCK for stimulating amylase secretion from dispersed pancreatic acini was similar in obese and lean rats (10(-10) M), less amylase was secreted in obese rats across the dose range tested (p less than 0.001). In contrast, carbachol had similar potency and efficacy in stimulating amylase release from obese and lean pancreatic acini. The increase of pancreas size by use of a trypsin inhibitor was greater in lean than obese rats (p less than 0.03). In addition, stimulation of amylase release by CCK from obese trypsin inhibitor-treated compared with control obese rats was greater than that from lean trypsin inhibitor-treated compared with control lean rats (p less than 0.002). However, overall, stimulation of amylase secretion by CCK was only 36% of control (p less than 0.001) and by carbachol was only 20% of control (p less than 0.001). Thus, increased size by increased cell number was associated with decreased response per cell.(ABSTRACT TRUNCATED AT 250 WORDS)
D000681:Amylases / Q000378:metabolism*; D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D002217:Carbachol / Q000494:pharmacology; D046508:Culture Techniques; D004247:DNA / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004952:Esters; D005260:Female; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology; D010446:Peptide Fragments / Q000378:metabolism*; D051381:Rats; D011924:Rats, Zucker; D011956:Receptors, Cell Surface / Q000187:drug effects* / Q000378:metabolism; D011949:Receptors, Cholecystokinin; D012844:Sincalide / Q000378:metabolism* / Q000494:pharmacology*
D004952:Esters; D006146:Guanidines; D010446:Peptide Fragments; D011956:Receptors, Cell Surface; D011949:Receptors, Cholecystokinin; C034532:camostat; C025997:cholecystokinin (27-33); D016670:Gabexate; D002217:Carbachol; D004247:DNA; D000681:Amylases; D012844:Sincalide